Apollomics, Inc. (APLM) Stock Analysis & Investment Frameworks
Apollomics, Inc. (APLM) stock analysis on Invetso. Review Apollomics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Apollomics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Apollomics, Inc. Key Financial Metrics
- Market Cap: $55.38M
- Revenue: $8.50M
- ROE: 288.40%
- ROIC: -1586.77%
- Dividend Yield: N/A
About Apollomics, Inc.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Apollomics, Inc. Investment Frameworks
Invetso analyzes Apollomics, Inc. (APLM) across the following frameworks:
- Apollomics, Inc. 10Y Growth Potential
- Apollomics, Inc. Scenario Analysis
- Apollomics, Inc. Risks & Opportunities
- Apollomics, Inc. Economic Moat
- Apollomics, Inc. Business Model
- Apollomics, Inc. Management
- Apollomics, Inc. SWOT Analysis
- Apollomics, Inc. Porter's 5 Forces
- Apollomics, Inc. PESTLE Analysis
- Apollomics, Inc. ESG Analysis